In this issue:
CT-P39 vs. omalizumab in CSU
Omalizumab, dupilumab & remibrutinib in CSU
Urticaria Voices: real-world patient experiences of CSU
Predictive value of total IgE for antihistamine response
Omalizumab discontinuation methods & relapse
Factors associated with relapse after omalizumab discontinuation
AIDUS: an urticaria support chatbot
Recommendations for CSU management
Skin prick tests in paediatric chronic urticaria
Please login below to download this issue (PDF)